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Abstract
Background: Recombinant protein purification is a crucial step for biochemistry and structural biology fields. Rapid
robust purification methods utilize various peptide or protein tags fused to the target protein for affinity purification
using corresponding matrices and to enhance solubility. However, affinity/solubility-tags often need to be removed
in order to conduct functional and structural studies, adding complexities to purification protocols.
Results: In this work, the Vibrio cholerae MARTX toxin Cysteine Protease Domain (CPD) was inserted in a ligation-
independent cloning (LIC) vector to create a C-terminal 6xHis-tagged inducible autoprocessing enzyme tag, called
“the CPD-tag”. The pCPD and alternative pCPD/ccdB cloning vectors allow for easy insertion of DNA and expression
of the target protein fused to the CPD-tag, which is removed at the end of the purification step by addition of the
inexpensive small molecule inositol hexakisphosphate to induce CPD autoprocessing. This process is demonstrated
using a small bacterial membrane localization domain and for high yield purification of the eukaryotic small
GTPase KRas. Subsequently, pCPD was tested with 40 proteins or sub-domains selected from a high throughput
crystallization pipeline.
Conclusion: pCPD vectors are easily used LIC compatible vectors for expression of recombinant proteins with a
C-terminal CPD/6xHis-tag. Although intended only as a strategy for rapid tag removal, this pilot study revealed
the CPD-tag may also increase expression and solubility of some recombinant proteins.
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Background
Ligation-independent cloning (LIC) represents a robust
and efficient cloning technique for recombinant proteins
[1]. This cloning method exploits the 3’-5’ exonuclease
activity of T4 DNA polymerase, which creates extended
segments of complementary DNA of the amplified gene
to facilitate the annealing with the target linearized vec-
tor. This procedure does not require classical endonucle-
ase restriction enzyme digestion or in vitro ligation. LIC
is suitable for high - throughput (HT) cloning platforms
used to produce large numbers of proteins without con-
sidering restriction cleavage sites for each gene of interest.
LIC is often used for rapid insertion of PCR products
where HT cloning for recombinant protein production
plays a fundamental role for the characterization of hun-
dreds of proteins [2, 3].
Fusion tags play significant roles in enhancement of
expression and solubility, and purification of target pro-
teins. A hexahistidine tag (6xHis-tag) is one of the most
frequently used fusion tags for affinity purification of re-
combinant proteins. Besides the 6xHis-tag, large soluble
affinity tags, such as glutathione S-transferase (GST),
maltose-binding protein (MBP), thioredoxin, the tran-
scription termination anti-termination factor NusA or
small ubiquitin-like modifier (SUMO) are often used to
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increase the solubility of recombinant proteins [4]. How-
ever, these affinity/solubility tags have to be removed
after purification in order to conduct functional studies
or crystallization [5]. Although large soluble tags enhance
soluble expression of recombinant proteins, sometimes
they cause misfolded and non-functional target proteins.
The much smaller 6xHis-tag is a frequently used peptide
tag for affinity purification, but it has been reported
that the highly-charged tag can negatively affect protein
crystallization and/or functional characterization [6, 7].
In order to remove any fusion tag, a protease cleavage
site is frequently incorporated at the junction between
the target protein and the affinity/solubility tag. Prote-
ases commonly used to specifically cleave fusion tags in-
clude thrombin, SUMO protease, Factor X, and Tobacco
Etch Mosaic Virus (TEV) protease. The efficiency of
proteolytic processing can sometimes be complicated by
steric hindrance or by unfavorable residues close to the
cleavage site. Additionally, large-scale protein production
can require a relatively large amount of the protease,
which may limit the final protein yield and significantly
increase the purification cost. Overall, affinity/solubility-
tag removal adds another layer of complexity and expense
to any purification process.
In the last decade, several self-cleaving tags have been
developed. These special fusion tags possess an inducible
activity, which can be triggered upon binding small mol-
ecules or conformational changes induced by particular
buffer conditions. Shen A. et al. [8] demonstrated that the
6xHis-tagged Cysteine Protein Domain (CPD) of Vibrio
cholerae could be fused at the C-terminus of the target pro-
tein and be used as self-cleavage fusion system. This tech-
nology was also developed independently by Northwestern
University [9, 10]. CPD is a highly conserved domain of the
large V. cholerae Multifunctional-Autoprocessing Repeats-
in-Toxin (MARTX) toxin [11]. Once translocated by the
toxin into the eukaryotic cytosol, the CPD is activated to
autoproteolyze the toxin by inositol hexakisphosphate
(InsP6), releasing several cytotoxic effector domains [11].
CPD cleaves after leucine residues located in accessible
loops, which are able to occupy the hydrophobic pocket of
S1 site [12, 13]. Although, only a leucine residue is strictly
required for CPD autoprocessing, leucine residues located
between small residues are preferred substrates [12, 13].
Since InsP6 is absent in bacteria cells, self-cleaving CPD fu-
sion systems have been used as versatile tool for expression
and purification of several proteins [12–14]. Moreover, the
6xHis-tagged CPD was demonstrated to improve expres-
sion, solubility, and stability of fusion proteins although the
vectors used standard restriction enzyme cloning [8].
In this work, we report a new vector designated pCPD
that incorporate sequences for a C-terminal 6xHis-tagged
CPD (the CPD-tag) in-frame with a LIC site. We success-
fully tested two different self-cleaving CPD fusion proteins
and compared the same proteins purified with a conven-
tional TEV protease-cleavable 6xHis-tag. Additionally,
pCPD was further modified by the insertion of a coupled
cell division B (ccdB) cassette as a negative selection marker
to create a vector more suitable for vector preparation and
high throughput LIC. The pCPD/ccdB vector was used for
HT cloning and demonstrated to improve success rates for
both expression and solubility after removing the CPD-tag
from recombinant proteins derived from a HT pipeline.
Methods
Enzymes and reagents
Restriction enzymes and Gibson Assembly® cloning re-
agents were obtained from New England Biolabs and poly-
merases were obtained from Life Technologies. TOP10
competent cells and InsP6 (also known as phytic acid)
were obtained from Sigma-Aldrich. Other common che-
micals, antibiotics, and growth media components were
from Sigma-Aldrich or Thermo Fisher.
Bacterial expression vectors for production of recombin-
ant proteins pMCSG7, pMCSG53, and pMCSG58 were ob-
tained from Dr. Andrzej Joachimiak of the Midwest Center
for Structural Genomics (MCSG). The vector pMCSG7
consists of a LIC site and encodes for an N-terminal TEV
cleavable 6xHis-tagged protein [15]. The vector pMCSG53
is an upgraded version of pMCSG7 that also carries the
rare codon tRNA genes argU and ileX [16]. The vector
pMCSG58 is similar to pMCSG53 except it encodes for a
C-terminal 6xHis-tagged protein [16]. Proteins were
expressed in kanamycin-resistant BL21(DE3)MAGIC E. coli
strain. The pMagic plasmid also provides a second copy of
the rare codon tRNA gene argU ([17] and A. Joachimiak,
personal communication).
New vectors for expression of CPD fusion proteins
Insertion of CPD into of pMCSG58 vector
DNA corresponding to coding sequence for amino acids
L3428-G3637 of the V. cholerae rtxA gene (vc1451, geneID
2613957) was amplified from purified V. cholerae N16961
chromosomal DNA using Pfx50 DNA polymerase, forward
primer 5’-CTTTAAGAAGGAGTCTCTCCCGGGGCAGC
ATTAGCGGATGG-3’ and reverse primer 5’-GATGATG
ATGGTGGTGAGCCCCACCTTGCGCG-3’. The vector
pMCSG58 was digested with SmaI restriction enzyme and
purified. 3 pmol of PCR product and 1 pmol of linearized
vector were incubated with Gibson Assembly® master mix
for 1 h at 50°C [18]. 1 μl of the Gibson cloning reaction was
transformed into TOP10 electro-competent cells. The final
plasmid pCPD was confirmed to be accurate by DNA
sequencing.
Incorporation of ccdB/CmR cassette
pCPD was modified by incorporating ccdB cassette at the
cloning site to prepare pCPD/ccdB for a HT LIC platform.
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The cassette of ccdB and CmR (chloramphenicol resistant
gene cat) in pDONR221 was amplified by polymerase
chain reaction using primers, 5’-TTAACTTTAAGAAG-
GAGTCTCTCCCGGG CTTCATCTGGATTTTCAGC’
and 5’-TTTTTCCATCCGCTAATGCTGCCCCGGG
TTATCGAGATTTTCAGGAGCTAA-3’. The 5’-end se-
quences of the oligonucleotides are pCPD vector specific,
the 3’-end sequences are ccdB/CmR cassette specific. The
SmaI cleavage sequence (CCCGGG) was incorporated
into the center of the oligonucleotides. The vector pCPD
was digested with SmaI. Both amplified ccdB/CmR cassette
and digested vector were gel-purified. 20 μl Gibson assem-
bly® reaction with 30 fmol purified insert and vector back-
bone was performed as previously reported [18]. 20 μl of
assembly reaction was transformed into ccdB survival TM
T1 Phage-resistant E. coli. Transformants were plated on
LB-agar containing 100 μg/mL ampicillin and 25 μg/mL
chloramphenicol. Selected transformants were grown in
2xYT with antibiotics for plasmid preparation. The final
plasmid pCPD/ccdB was confirmed by DNA sequencing.
Cloning, expression, and purification of MLDVv
DNA sequences corresponding to the membrane
localization domain (MLD, NP_759056.1, amino acids
Q3591-L3674) was amplified from purified V. vulnificus
CMCP6 chromosomal DNA using forward primer 5’-
GTCTCTCCCATGCAAATCTTTACGGTGCAAG
AGCT-3’ and reverse primer 5’-TGCTGCCCCCAACGCA
CTGGTGACCTGCT-3’ and the products were cloned into
SmaI-digested pCPD by LIC [1]. The plasmid was con-
firmed to be accurate by DNA sequencing and then trans-
formed into E. coli BL21(DE3)/MAGIC. Culture was grown
in Terrific Broth supplemented with 100 μg/mL ampicillin
and 30 μg/mL of kanamycin at 37 °C until OD600 = 0.8 and
then induced with 1 mM isopropyl-β-D-thiogalactoside
(IPTG) at 25 °C for ≈ 18 h. Bacteria were harvested by cen-
trifugation, re-suspended in buffer A1 (10 mM Tris pH 8.3,
500 mM NaCl, 0.1% Triton X-100, 1 mg/ml lysozyme, 5
mM β-mercaptoethanol (BMe) and lysed by sonication.
After centrifugation at 30,000xg for 30 min, the soluble
lysate was incubated with Ni-NTA resin (GE Health-
care) for 30 min at 4 °C. The Ni-NTA resin was recov-
ered onto a gravity column and washed with buffer B1
(10 mM Tris pH 7.5, 500 mM NaCl, 50 mM imidazole)
followed by elution in the same buffer with 500 mM
imidazole (buffer C1). Protein was exchanged into buffer
A1 (without Triton X-100) using a PD10 desalting column
(GE Healthcare). The protein solution was incubated with
100 μM InsP6 for 1 h at 25 °C under gentle agitation and
then loaded again onto the gravity column containing
Ni-NTA (GE Healthcare), the flow through fraction
containing the MLD was collected. Purified proteins were
analyzed by SDS-PAGE.
KRas expression and functional characterization
Cloning, expression, and purification KRas
KRas full-length (fl) and KRas catalytic domain (residues
1–169) were amplified by PCR from a plasmid template
containing the full-length KRas gene [19]. In order to in-
sert KRas-fl and KRas1–169 into pMCSG7 and pCPD,
three different set of primers were designed and used:
KRas-fl-pCPD-FWD 5’-CTTTAAGAAGGAGTCTCTCC
CATGACTGAATATAAACTTGTGGTAGTTGGAGCT








AACTT GTGGTAGTTGG-3’ - KRas1–169-pCPD-REV
5’-CCGCTAATGCTGCCCCCTTTTCTTTATGTTTTC
GAATTTCTCGAACTAATG-3’) for Gibson Assembly®
cloning method. The vectors pMCSG7 and pCPD were
digested with SspI or SmaI, respectively. PCR products
(KRas1–169-pMCSG7, KRas-fl-pCPD and KRas1–169-pCPD)
and linearized vectors were gel-purified. 10 μl of Gibson
Assembly® master mix, 1 pmol pMCSG7 or pCPD linear-
ized vectors and 3 pmol the respective PCR products were
incubated for 1 h at 50 °C. 1 μl of the Gibson Assembly® re-
action mix was transformed into TOP10 electro-competent
cells. Plasmids were confirmed to be accurate by DNA se-
quencing and then transformed into E. coli BL21(DE3)/
MAGIC. All KRas fl proteins were expressed as described
above for MLD. KRas1–169-CPD and KRas1–169 were puri-
fied as described here. Bacteria were harvested by centrifu-
gation, re-suspended in buffer A1 (50 mM Tris pH 8.3, 500
mM NaCl, 10 mM MgCl2, 0.1% Triton X-100, 5 mM BMe)
and lysed by sonication. After centrifugation at 30,000xg for
30 min, the soluble lysates were loaded onto a 5-ml
HisTrap column using the ÄKTA Purifier system (GE
Healthcare). The column was washed with buffer B1 (10
mM Tris pH 7.5, 500 mM NaCl, 10 mM MgCl2, 50 mM
imidazole) followed by elution in the same buffer with 500
mM imidazole (buffer C1). Proteins were further purified
by size-exclusion chromatography (SEC) (Superdex 200
(26/60), GE Healthcare) in buffer D1 (10 mM Tris–HCl pH
7.5, 500 mM NaCl, 10 mM MgCl2, 5 mM BMe). The
6xHis-tag of KRas1–169 expressed from pMCSG7 was
cleaved overnight with TEV protease and further purified
by removal of uncleaved protein using a HisTrap column
(GE Healthcare). The KRas1–169-CPD fusion protein was
incubated with 100 μM InsP6 (Sigma Aldrich) for 1 h at 25
°C under gentle agitation. The protein sample treated with
InsP6 was loaded onto a HisTrap column (GE Healthcare)
and the flow through fraction containing KRas1–169-GAAL
was collected. Purified proteins were analyzed by SDS-
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PAGE. The Coomassie stained gel was scanned and band
intensity of each recombinant protein was quantified using
the NIH ImageJ v1.49 software.
Cloning, expression, and purification of GAP-334
Sequence of GAP-334 (residues 712–1046) was ampli-
fied from a plasmid containing the p120 sequence found
in the KRAS Entry and RAS Pathway Clone Collection




GGTTTTTGTATAC-3’. The PCR product was cloned
into pMCSG7 as described for KRas1–169 above. Plasmids
were confirmed to be accurate by DNA sequencing and
then transformed into E. coli BL21(DE3)/MAGIC. GAP-
334 protein was expressed and purified as described above
for KRas1–169, except all buffers were adjusted to pH 8.3.
Purified protein was analyzed by SDS-PAGE.
KRas Single-turnover GTP hydrolysis
Single-turnover GTP hydrolysis analysis was performed
as previously described [20]. All buffers were made
phosphate-free by dialysis with 2 U of nucleoside phos-
phorylase and 0.5 mM of inosine. Briefly, for intrinsic
hydrolysis, 20 μM of Ras was used. For GAP-mediated
hydrolysis GAP-334 was used at final concentration of
0.2 μM and 0.1 μM, in order to have a GAP:Ras ratio of
1:100 and 1:200 respectively. FlippiU purified from vec-
tor pRSET FLIPPi-5u (Addgene) as previously described
[21] was used to detect in real-time the amount of inor-
ganic phosphate released in solution by the GTP hy-
drolysis [21]. The ratio of fluorescence emission 480/530
nm was measured with an excitation of 435 nm on Spec-
traMax M3 (Molecular Devices). Data were converted to
phosphate concentration using a standard curve. Data
were fit in GraphPad Prism 6.0 to a one-phase exponen-
tial association curve to determine the kobs. All reactions
were performed in triplicate.
Compare HT expression and protein solubility
PCR amplification of target ORFs and cloning into two
vectors
Forty protein targets representing the next forty proteins
or subdomains in the HT structural determination pipeline
of the CSGID were selected. Two LIC expression vectors,
pCPD/ccdB and pMCSG53/ccdB were used for protein
expression and target open reading frames (ORFs) were
amplified by PCR. In order to clone into pCPD/ccdB
vector, PCR primers were designed such that gene spe-
cific sequences were followed by vector specific regions
5’-GTCTCTCCC, and 5’-TGCTGCCCC in forward pri-
mer and reverse primer, respectively. For pMCSG53/ccdB,
vector specific region sequences, 5’-TACTTCCAATCCA
ATGCG and 5’-TTATCCACTTCCAATG were added to
forward and reverse primers. PCR amplification of ORFs
was performed using a standard PCR condition.
The PCR products for pCPD were treated with T4
DNA polymerase in the presence of dTTP. The LIC vec-
tor, pCPD/ccdB was digested with SmaI (5U/μL DNA)
to remove ccdB and treated with T4 DNA polymerase in
the presence of dATP, After T4 DNA polymerase treat-
ment, 0.02 pmol of vector DNA and 0.04 pmol of insert
DNA were mixed and annealed at 22 °C for 30 min as
previously described [15]. 2 μL of the reactant was trans-
formed into 25 μL of chemically competent E. coli
DH5α using the heat shock method.
Cloning into pMCSG53/ccdB used a modified method
of cloning for pMCSG7 as previously described [15]. PCR
product and vector backbone from linearized pMCSG53/
ccdB were treated with T4 DNA polymerase in the pres-
ence of dCTP and dGTP, respectively. Annealing of vector
backbone and PCR and transformation into DH5α were
performed as described above for cloning targets into
pCPD.
Protein Expression Screening and Cleavage
The forty plasmids for each vector system were trans-
formed to E. coli BL21(DE3)/MAGIC. Cells were grown in
1 mL 2xYT in a 96-well block at 37 °C at 900 rpm using a
multitron shaker. Once cells reached an OD600 = 0.8, gene
expression was induced by adding IPTG to a final concen-
tration of 1 mM and incubating at 25 °C for 18–20 h. Cells
were pelleted by centrifugation at 2,200xg for 30 min at
4 °C and stored at −80 °C. Cell pellets were thawed and
resuspended in lysis buffer (50 mM Tris–HCl, 5 mM
imidazole, 300 mM NaCl, 1mM dithiothreitol (DTT)
pH 7.8 at 4 °C) and lysed by adding PopCulture Re-
agent (EMD-Novagen). Aliquots of cell lysates were
transferred to a new 96-well plate and the remaining
were centrifuged at 2,200xg for 1 h to separate the sol-
uble fraction. The soluble fractions were transferred to
a 96-well plate. Whole lysate and supernatant fractions
were processed on the LabChip GXII (Perkin Elmer,
Waltham, MA) to examine expression and solubility
level of N-terminal 6xHis-tag fused target proteins. C-
terminal CPD-tag fused recombinant proteins were
purified using Ni-NTA agarose resin in a 96-well block
as previously described [22]. The recombinant proteins
were eluted in 200 μL elution buffer (50 mM Tris–HCl,
200 mM imidazole, 300 mM NaCl, 1mM DTT pH 7.8
at 4 °C). The purified proteins were exchanged into a lysis
buffer and concentrated using a 96-well Multiscreen filter
plate with an Ultracel-10 membrane (EMD-Millipore,
Billerica, MA). The CPD-tag of the recombinant proteins
were activated by adding InsP6 to a final concentration of
100 μM and incubating for 2 h at room temperature. The
cleaved 6xHis-tagged CPD was removed by adding 25 μL
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Ni-NTA agarose resin and incubated for 30 min at 4 °C.
The target proteins were transferred into a new 96-well
plate. Whole lysates and supernatants and purified and
cleaved proteins were examined HT capillary electrophor-
esis (LabChip GXII) and/or NuPAGE with Coomassie
blue staining (Additional file 1: Figure S1). As previously
reported [23], the level of expression and solubility of
recombinant proteins were scored as four categories: 0
(undetectable), 1 (low), 2 (medium), and 3 (high)
(Additional file 2). The scale is approximately, 0: <2%,
1: 2-10%, 2: 5–10%, 3: >10%. The purity percentage was
obtained directly from LabChip HT software.
Results and discussion
Design and development of self-cleavage LIC/CPD fusion
system
The cpd DNA sequence was amplified with LIC primers
specific for SmaI-digested the vector pMCSG58 [16],
which was used as backbone for the creation of the LIC/
CPD fusion system (Fig. 1a). pMCSG58 is a bacterial ex-
pression vector that encodes a C-terminal 6xHis-tag and
additionally contains a LIC site and argU and ileX genes for
rare codon tRNAs [16]. The forward primer was designed
with extra nucleotides in order to restore the LIC site and
SmaI restriction site after the insertion of cpd sequences. In
Fig. 1 Design and cloning strategy of pCPD. a Sequence of LIC site in pMCSG58; b Sequence of LIC site in pCPD; c Molecular cloning strategy for
the pCPD vector. After SmaI digestion linearized pCPD is treated with T4 polymerase and dATP. Target protein is amplified by PCR using LIC
primers. PCR product is treated with T4 polymerase and dTTP. Both vector and PCR product are mixed for annealing and then transformed into
competent cells
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the newly created vector pCPD, the sequence for the LIC
site is in frame with codons for the CPD followed by a
6xHis-tag (Fig. 1b). This vector pCPD is thus designed
to express recombinant proteins with a CPD-tag at the
C-terminus both to mimic its natural activity and because
it is currently unknown whether N-terminal CPD-tag can
efficiently autoprocess its own C-terminus [12]. DNA se-
quences of a target protein can be cloned into pCPD by
LIC with T4 DNA polymerase or by Gibson Assembly®
[18] (Fig. 1c) or other commercial direct cloning methods.
The protein fusion resulting from expression of DNA se-
quences cloned into pCPD will have four additional resi-
dues Gly-Ala-Ala-Leu at the junction between the target
protein and the CPD (Fig. 1c). These four residues repre-
sent the encoded sequence for LIC and provide a Leu and
a flexible linker for insertion into the CPD active site. The
addition of InsP6 to a purified fusion protein will trigger
activation of CPD proteolytic activity and the recombinant
protein will be cleaved after the Leu (Fig. 1c).
The C-terminal CPD-tag was previously proposed as a
rapid single-step purification strategy for the 6xHis-tag
removal while still bound on the initial column [8].
However, many biochemical studies require recombinant
proteins with high purity and integrity. Thus, we sought
to develop a purification protocol using a two-step re-
moval/purification process rather than single step. For high
efficiency of cleavage, the uncleaved CPD fusion protein is
first eluted from Ni-NTA column followed by a second
desalting or size exclusion step to remove imidazole and
protein aggregates from the CPD protein-fusion (Fig. 2a).
The CPD fusion-protein is then treated in solution with
InsP6, triggering CPD autoprocessing and thereby releas-
ing the target protein. The cleaved CPD-tag is separated
from the target protein by an additional passage over a
Ni-NTA column (Fig. 2a).
In order to test the feasibility of the system to purify
small proteins, purification of the 83 amino acid MLD
from the V. vulnificus MARTX toxin Ras/Rap1 Specific
Protease (RRSP) [19, 24] was conducted. MLD is a 10 kDa
protein while CPD is 27 kDa and as shown in the Fig. 2b,
the fusion protein ran at the expected molecular weight
on an SDS-polyacrylamide gel. Imidazole in the elution
buffer was removed using a desalting column and the
protein solution was adjusted to 100 μM InsP6. After
an hour, the fusion protein was completely cleaved.
The MLD was separated from the CPD-tag by incu-
bating the protein solution with Ni-NTA resin and
collecting the unbound fraction (Fig. 2b). As shown
in the Fig. 2b, the MLD cleaved by CPD (MLDGAAL)
ran at the expected molecular weight.
Using pCPD vector for expression of highly soluble KRas
To test for successful purification of a eukaryotic protein,
Ras, a human oncoprotein involved in the regulation of
cell proliferation, differentiation and survival [25, 26]. Al-
though recombinant Ras proteins are well expressed in E.
coli, the final purification yield of the isoform KRas is
low due to the formation of inclusion bodies [27]. To
test whether our self-cleavage system could improve
KRas yield, we cloned the full-length KRAS gene se-
quence or the sequence corresponding to the catalytic
domain (KRas1–169) into pCPD. For comparison to an
alternative expression system, the genes were also cloned
into pMCSG7, which was previously used for KRas pro-
duction [19]. The vector pMCSG7 has the LIC site and
encodes for an N-terminal 6xHis-tag and TEV cleavage
site [15].
Although the protein expression for each construct
was similar, KRas-CPD and KRas1–169-CPD were highly
soluble (Fig. 3a and b). In particular, KRas1–169-CPD was
three times more soluble than N-terminal 6xHis-tagged
KRas1–169 (6xHis-TEV-KRas) expressed from the vector
pMCSG7 and KRas-CPD was four times more soluble
than N-terminal 6xHis-tagged KRas (Fig. 3b). KRas1–169-
CPD and 6xHis-TEV-KRas1–169 were each purified to
quantify the final purification yield and to check for
function in a GTPase activity assay. Lysates containing
each protein were loaded onto a Ni-NTA column and
eluted in imidazole buffer as the first step of purification.
Subsequently, KRas1–169-CPD and 6xHis-TEV-KRas1–169
were subjected to SEC. Elution fractions containing
KRas1–169-CPD were pooled and treated with 100 μM
InsP6. After 10 min, 30 min and 1 h, protein samples
were collected to check CPD autoprocessing. After 1 h,
the protein fusion was cleaved and the solution contain-
ing KRas1–169-GAAL and the CPD-tag were passaged across
a Ni-NTA column (Fig. 3c). KRas1–169-GAAL was recovered
into the flow-through fraction with a final yield of 35 mg/L.
Separately, purified 6xHis-TEV-KRas1–169 was incubated
overnight with TEV protease, then the protein solution was
loaded onto Ni-NTA column and the flow-through fraction
was collected, the final protein yield was 11 mg/L. Both
KRas1–169 and KRas1–169-GAAL were separated by SDS-
PAGE showing high purity and expected similar molecular
weight (Fig. 3d).
In order to compare the catalytic activities of the
two different KRas proteins, GTPase activity was per-
formed using FlippiU as a protein sensor for inorganic
phosphate released in solution (Fig. 3f). KRas1–169 and
KRas1–169-GAAL showed the same magnitude of intrinsic
and GAP-mediated GTP hydrolysis activities, suggesting
that there were no functional differences between the
proteins.
Developing pCPD with a ccdB cassette for HT cloning
LIC vectors are usually prepared by restriction digestion
and agarose-gel excision. Although the gel purification de-
creases background transformation after LIC, the digested
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vector is difficult to separate from the relaxed undigested
vector. Therefore, even after agarose-gel purification, there
is potentially still contamination with undigested vector,
which can decrease the number of plasmids containing
the target gene inserted, reducing the success rate in the
HTcloning platform.
In order to improve cloning efficiency for the purpose
of HT cloning, the vector pCPD was further modified by
insertion of the ccdB gene, which encodes for a cytotoxin
that targets DNA gyrase [28] (Fig. 4). The ccdB gene then
acts as a negative selection marker, because transformed
cells with incomplete or undigested vector will not
survive after LIC due to the presence of ccdB [29–31].
Thus, the advantage of the ccdB insertion is that only
fully digested plasmids that have successfully incorpo-
rated the target gene insert are transformable. To in-
sert ccdB, pCPD was digested with SmaI, and the PCR
amplified 1823 bp ccdB and chloramphenicol resistance
Fig. 2 Purification strategy of autoprocessing CPD fusion-tag. a Self-cleaving CPD-fusion protein purification; b Purification of MLD. Marker (M),
Total proteins (Tot), Soluble proteins (Sol), Washing step with 50 mM imidazole (W), Elution step with 500 mM imidazole containing MLD-CPD
(E1), 1 h incubation with InsP6 (InsP6), First flow-through fraction containing MLD (FT1), Second flow-through fraction (FT2), Elution step with 500
mM imidazole containing CPD (E2), and previously purified MLD (MLD)
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gene cassette (ccdB/CmR) were ligated into the site.
In order to avoid loss of the LIC site, two SmaI sites
were incorporated into the PCR primers, such that
SmaI digestion of the final pCPD/ccdB vector is identi-
cal to that from unmodified pCPD when linearized
(Fig. 4).
Use of pCPD increases expression and solubility fusion
proteins
To more broadly investigate the applicability of this
method, we utilized resources of the National Institute
of Allergy and Infectious Diseases (NIAID) Center for
Structural Genomics of Infectious Disease (CSGID,
Fig. 3 Expression and purification of KRas with pCPD and pMCSG7. a-b Expression and solubility of KRas1–169 and KRas fl. The amount of expressed
and soluble proteins were analyzed by SDS-PAGE and measured with ImageJ software. Bars are the average of three independent biological replicates;
c Marker (M), Total proteins (Tot), Soluble proteins (Sol), Elution step with 500 mM imidazole containing KRas1–169 -CPD (El), protein concentration step
(C), SEC step (SEC), incubation time with InsP6, 10, 30 and 60 min respectively (10’-30’-60’), Flow-through fraction containing KRas1–169 -GAAL (FT);
d SDS-PAGE of KRas1–169 and KRas1–169 –GAAL; e-f Intrinsic and GAP mediated single-turnover GTP hydrolysis for KRas1–169 and KRas1–169 –GAAL.
GAP-334 was used at two different molar ratios of 1:100 and 1:200 (GAP:KRas). Each curve and bar represent the average of three
independent biological replicates
Fig. 4 Molecular cloning strategy of pCPD/ccdB
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http://csgid.org), which conducts HT cloning, protein
production, and protein crystallization as an NIAID
community resource. The next 40 CSGID target genes
from this pipeline were selected to perform an unbiased
pilot analysis of the impact the new pCPD vector could
have on HT strategies. These 40 proteins include 36
unique bacterial proteins and 4 subdomains from 13 dif-
ferent species, although the majority (22 proteins) are pro-
teins related to the type 2 secretion system (T2SS) from
Klebsiella pneumoniae. The target genes were amplified
by PCR, inserted into pCPD/ccdB, and expressed from the
T7 promoter. As a control, the same fragments were
cloned and expressed using pMCSG53/ccdB, a vector that
expresses proteins fused to an TEV cleavable N-terminal
6x-His tag similar to pMCSG7 except that the plasmid
also carries the rare tRNA codon genes ileX and argU
(similar to pCPD/ccdB derived from pMCSG58) [16].
For all the recombinant proteins produced, the whole
cell lysate and the supernatant fluid from induced cells
were analyzed by SDS-PAGE and scored (Additional files
1 and 2). Twenty-eight (70%) of the CPD-fusion proteins
were expressed when the genes were induced in E. coli
compared to only 18 (45%) of those expressed with a
TEV cleavable N-terminal 6xHis-tag (Fig. 5a). Sixteen
HT targets were successfully expressed from both vectors,
12 were expressed exclusively from pCPD, while two were
expressed exclusively from pMCSG53 (Fig. 5b). In terms
of solubility, out of the 28 expressed CPD-fusions proteins,
24 (60%) were soluble, while 13 of the 18 expressed N-
terminal 6xHis-tagged proteins were found in the super-
natant fluid after lysis (Fig. 5b). In addition, three of the 16
proteins that were expressed from both plasmids were sol-
uble only when expressed fused with CPD (Fig. 5b). Thus,
the CPD functions not only as an easy strategy to remove
a 6xHis-tag, but also enhances the success rate of protein
expression and solubility.
A major concern of the use of solubility tags is that
proteins become insoluble upon tag removal. 16 of the
24 soluble CPD-fusions proteins were still soluble upon
processing (Table 1). Thus, an HT strategy employing only
pCPD would be expect to return 40% soluble proteins
with tags removed. This is comparable or slightly better
than an HT strategy dependent only on pMCSG53, which
returned 33% (13/40) soluble proteins with the 6xHis-tag.
Since removal of small 6xHis-tags does not generally re-
sult in protein insolubility, cleavage by TEV protease was
not done and would not be expected to change this fre-
quency. Of note, some proteins that were soluble from
each vector were not the same (Additional file 2), such
that an HT strategy that would employ both expression
vectors in a side-by-side approach would be predicted to
yield 53% soluble protein. Notably, since conducting this
pilot, two structures deposited to PDB (ID 5DO8 [32] and
5F7S [33]) have been determined for proteins purified
Fig. 5 Expression and solubility of 40 bacterial proteins produced
with pCPD and pMCSG53. a Percentage or b Number of expressed
and soluble proteins resulting from expression of 40 selected target
proteins from the indicated vector or vectors. n.d., not done
Table 1 Summary of success frequencies in expression of 40
recombinant proteins in E. coli using two expression vectors,
pCPD and pMCSG53a
pCPD pMCSG53 Combined
Total target proteins 40 40 40
Expressed proteins in E. coli 28 (70%) 18 (45%) 30 (75%)
Soluble proteins 24 (60%) 13 (33%) 26 (65%)
Purified recombinant proteins 20 (50%) n.d. n.d.
Soluble cleaved proteins 16 (40%) n.d. 21b (53%)
an.d., not done
bCombined soluble proteins expressed using pMCSG53 (uncleaved) and
soluble cleaved proteins expressed using pCPD
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from pCPD, indicating that the presence of the 4 aa on the
C-terminus does not interfere with crystallization. For
these two proteins, CPD autoprocessing was performed at
4 °C overnight. This, together with previously tested con-
ditions including 0.4 M urea [12], suggest that the removal
of the CPD-tag can be achieved within a broad range of
temperature from 4 °C to 37 °C and for different amount
of time from 1 min to overnight without compromising
the CPD activity.
Conclusions
In this work, a new vector, pCPD, was developed for
overexpression of recombinant proteins with a C-terminal
fusion to CPD-tag inducible by InsP6 to remove itself by
autoprocessing. This new vector has several advantages
over previous CPD-fusion vectors that depended on
classical restriction enzyme gene insertion [8]. First, the
backbone vector pMCGS58 provided a site for easy inser-
tion of genes for protein expression by LIC or by recom-
bination methods such as Gibson Assembly® and rare
codons genes ileX and argU for improved success in pro-
tein expression. The pCPD vector was initially tested for
two target proteins that had previously proven difficult to
purify due to small size and insolubility, MLD and KRas,
respectively. Interestingly, pCPD was shown to increase
significantly the solubility of KRas1–169. Intrinsic and GAP
stimulated GTP hydrolysis of KRas1–169-GAAL was equally
active to KRas1–169 purified with an N-terminal 6xHis-tag.
In addition, the developed purification protocol can be
easily applied to a high yield-high purity, two-step produc-
tion scale purification strategy of Ni-NTA followed by
SEC. Strategies for single step purification and cleavage
could also be developed and useful when protein yield and
purity are not as essential as they are in structural deter-
mination and biochemical assessment.
The vector pCPD was then further modified to contain
ccdB cassette in order to increase cloning efficiency. Using
a pilot set of 40 proteins, the CPD-tag was unexpectedly
shown to increase the rate of success for expression and
solubility of recombinant proteins by 23% when compared
with proteins expressed with a TEV protease cleavable
6xHis-tag. Thus, pCPD and pCPD/ccdB are excellent
options both to be implemented as a first line approach
to recombinant protein expression and solubility, or as a
side-by-side alternative to standard TEV protease cleavable
tags for successful recombinant protein production.
Additional files
Additional file 1: Figure S1. Sixteen representative samples of proteins
expressed from vector pCPD show diversity of expression, solubility and
recovery after InsP6 induced autoprocessing. Numbers at top indicate
CSGID IDP designation as listed in Additional file 2. Lanes for each
sample represent Whole cell lysate (L), Soluble fraction from lysate (S),
Purified fusion protein (P), and purified protein after CPD autoprocessing
(P’). Figure was assembled from multiple SDS-polyacrylamide gels stained
with Coomassie Blue. The scores at each stage and the total amount of
purified protein after autoprocessing are shown below the gel figure. The
amounts of total purified proteins from 1 mL cultures were determined
from absorbance at 260 nm using a NanoDrop. (TIFF 830 kb)
Additional file 2: Table S1. List of proteins examined for expression and
solubility. IDP# Identification protein number relative to CSGID targets
(http://csgid.org/); Locus ID for NCBI; Expression: expressed proteins are
highlighted in yellow (1-Low expression, 2-Medium expression, 3-High
expression). Non-expressed proteins are highlighted in white; Solubility:
soluble proteins are highlighted in yellow (1-Low solubility, 2-Medium
solubility, 3-High solubility). Non-soluble proteins are highlighted in white
(0-undetectable solubility); Purified: proteins purified by single step on
Ni-NTA resin and desalting. Purified proteins are highlighted in yellow
(1-Low solubility, 2-Medium, 3-High). Non-purified proteins are highlighted
in white (0-undetectable); InsP6 cleavage: proteins cleaved by InsP6 CPD
autoprocessing activation and purified by “negative” Ni-NTA purification
step. Soluble proteins after the cleavage are highlighted in yellow (1-Low
solubility, 2-Medium, 3-High). Proteins lost after InsP6-cleavage/Ni-NTA
purification are highlighted in white (0-undetectable). (XLSX 16 kb)
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